Cadema Sells Off Shares of Monoclonal

WASHINGTON — Cadema Corp. said it has sold 41,300 shares of Monoclonal Antibodies Inc., according to documents filed with the Securities and Exchange Commission.

Cadema said it has reduced its stake in Monoclonal Antibodies of Mountain View, Calif., to 141,000 shares or 3.96% of the common stock outstanding. Cadema had held 182,300 shares or 5.12%.